Related references
Note: Only part of the references are listed.Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer
John M. S. Bartlett et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The 2011 EBCTCG polychemotherapy overview
Carlo Palmieri et al.
LANCET (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
Maria T. Baquero et al.
BREAST CANCER RESEARCH (2011)
BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy
Charles Dumontet et al.
CLINICAL CANCER RESEARCH (2010)
Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin
Yu-Yun Shao et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
Hirokuni Ikeda et al.
BREAST CANCER RESEARCH (2010)
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
George Pentheroudakis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
Satoru Tanaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
Lajos Pusztai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis et al.
LANCET (2009)
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials
Michele De Laurentiis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) -negative, but with grade in those with ER-Positive early-stage breast cancer suitable for cytotoxic chemotherapy
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2007)
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial:: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
A. Rody et al.
BREAST (2007)
Benefit of taxanes as adjuvant chemotherapy for early breast cancer - Pooled analysis of 15,500 patients
Emilio Bria et al.
CANCER (2006)
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
M Trudeau et al.
LANCET ONCOLOGY (2005)
Microtubule associated protein (MAP)-Tau - A novel mediator of paclitaxel sensitivity in vitro and in vivo
P Wagner et al.
CELL CYCLE (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
R Rouzier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: A systematic review
M Trudeau et al.
CANCER TREATMENT REVIEWS (2005)
Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses
PC Austin et al.
STATISTICS IN MEDICINE (2004)
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer
AK Nowak et al.
LANCET ONCOLOGY (2004)
Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience
J Crown et al.
ONCOLOGIST (2004)
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol
S Kar et al.
EMBO JOURNAL (2003)
Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond
FJ Esteva et al.
ONCOLOGIST (2001)
Share Paper
